Observational Study of the LambdaGuide System for Measurement of Observable Genitourinary Anatomy During Cystoscopic Procedures in Men

October 27, 2026 updated by: Lambda Surgical, Inc

This prospective clinical study will evaluate the feasibility, performance, and safety of the LambdaGuide System for obtaining point-to-point measurements of observable genitourinary anatomy during cystoscopic procedures in adult men. The system is intended to provide measurements of anatomical structures visible during cystoscopy without influencing clinical diagnosis or treatment decisions.

The study will assess successful calibration, spatial capture, measurement point selection, and completion of point-to-point measurements. Device usability, procedural workflow effects, and adverse events will also be evaluated. Optional comparisons with known-dimension references may be performed for descriptive purposes.

LambdaGuide measurements will not be used to guide or modify clinical care.

Study Overview

Status

Recruiting

Detailed Description

This is a prospective, observational clinical study designed to evaluate the feasibility, functional performance, usability, and safety of the LambdaGuide System during cystoscopic procedures in adult male participants aged 22 years and older.

The LambdaGuide System is an investigational optical measurement system that integrates with a compatible cystoscope. It uses an optical camera module, calibration process, spatial capture, and software-based point selection to obtain point-to-point measurements of anatomical structures visible within the urinary tract.

Participants may include men undergoing non-emergency cystoscopic procedures and, where specifically authorized under the approved research protocol, healthy adult male volunteers. Study participation involves use of the LambdaGuide System during cystoscopic visualization. For patients undergoing clinically indicated cystoscopy, the investigational measurements are performed alongside standard clinical care. LambdaGuide measurements will not be used to make diagnostic or therapeutic decisions, select treatment, or modify standard clinical care.

During the procedure, qualified clinicians will set up the LambdaGuide System, perform calibration using an approved calibration target, and attempt measurements of observable urinary anatomy. Potential measurement targets include anatomical openings or narrowing, urethral strictures, distances between anatomical landmarks, urinary tract lesions, stones, foreign bodies, and implant-related structures.

For each measurement attempt, the study will document the ability to obtain spatial information, select two valid measurement points, and display a point-to-point measurement. The primary performance endpoint is procedure-level clinical measurement feasibility, defined as obtaining at least one successful point-to-point measurement during an evaluable procedure.

Additional assessments include calibration success, camera deployment and image display, spatial capture success, measurement completion, calibration and measurement time, procedural interference, and clinician-reported usability. Optional observational comparisons with known-dimension references may be performed. These comparisons are descriptive and are not intended to establish measurement accuracy.

Safety will be evaluated through documentation of adverse events, including their severity, seriousness, and relationship to the investigational device or study procedures. Device deficiencies and malfunctions will also be recorded. Participants will undergo post-procedure safety assessment and follow-up approximately 30 days after the procedure, within a permitted window of ±5 days.

The study is intended to characterize the LambdaGuide System's ability to obtain measurements of visible genitourinary anatomy in a clinical environment and to collect performance, usability, and safety data to support further device evaluation.

Study Type

Observational

Enrollment (Estimated)

10

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02111
        • Recruiting
        • PINE (Prostate Institution of New England)
        • Contact:
        • Principal Investigator:
          • Louis Liou, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

22 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Sampling Method

Non-Probability Sample

Study Population

No additional description beyond Eligibility Criteria. Subjects should be able to travel to a study site.

Description

Inclusion Criteria:

  1. Adult male subject (22 years of age or older).
  2. Subject who undergoes a non-emergency cystoscopic procedure, or a healthy volunteer.
  3. Able and willing to provide informed consent before study participation.
  4. Procedure is expected to provide visualization of observable urinary anatomy suitable for an attempted measurement.
  5. Investigator determines that study participation is appropriate and will not interfere with standard clinical care.
  6. Investigator determines, based on medical history and physical examination, that the subject is medically appropriate to undergo the study procedures.

Exclusion Criteria:

  1. Participation is expected to interfere with or materially delay standard clinical care.
  2. Known clinical condition or procedural circumstance that, in the investigator's judgment, makes study participation inappropriate.
  3. Inability to provide informed consent.
  4. Inability to use the required compatible cystoscope or approved study configuration.
  5. Known allergy or contraindication to the local anesthetic planned for the cystoscopic procedure.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_ONLY
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical measurement feasibility
Time Frame: Procedure duration

Clinical measurement feasibility, assessed as a procedure-level pass/fail outcome. An evaluable procedure passes if at least one successful point-to-point measurement is obtained.

Procedure duration
Primary safety endpoint
Time Frame: From procedure date to 30 days after (+/-5 days)

Incidence, severity, seriousness, and relatedness of device-related, procedure-related, and other adverse events.

From procedure date to 30 days after (+/-5 days)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Calibration success
Time Frame: During Procedure

Calibration success

During Procedure
Camera deployment and expected image display
Time Frame: During Procedure

Camera deployment and expected image display

During Procedure
Spatial capture success
Time Frame: During Procedure

Spatial capture success

During Procedure
Valid point-selection success
Time Frame: During Procedure

Valid point-selection success

During Procedure
Successful measurement completion
Time Frame: During Procedure

Successful measurement completion

During Procedure
Calibration and measurement time
Time Frame: During Procedure

Calibration and measurement time (descriptive only)

During Procedure
Procedure interference
Time Frame: During Procedure

Procedure interference

During Procedure
User acceptance
Time Frame: During Procedure

User acceptance - based on Investigator Questionnaire

During Procedure
Observational comparative measurements (
Time Frame: During Procedure

Observational comparative measurements (descriptive only)

During Procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Louis Liou, MD, PhD, PINE - Prostate Institution of New England

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

October 1, 2027

Study Completion (Estimated)

October 1, 2027

Study Registration Dates

First Submitted

October 27, 2026

First Submitted That Met QC Criteria

October 27, 2026

First Posted (Actual)

November 3, 2026

Study Record Updates

Last Update Posted (Actual)

November 3, 2026

Last Update Submitted That Met QC Criteria

October 27, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe